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INTRODUCTION
Metabolic syndrome is a multifactorial disorder associated with development of 
cardiovascular,  neurological,  immunological,  renal  and  endocrine  disease.  Metabolic 
Syndrome is rapidly becoming the primary cause for  morbidity  and mortality  in the 
industrialized world surpassing infection, trauma and smoking related disorders.
Though  spontaneous  association  of  multiple  metabolic  abnormalities  were 
identified decades ago, Gerald M.Reaven introduced the concept of syndrome X where, 
impaired  insulin  action  could  constitute  the  common  ground  for  hypertension, 
dyslipidemia and diabetes mellitus1. However he does not include obesity which was 
commonly associated with the syndromic condition.
The  guidelines  issued  by  Adult  Treatment  Panel  III(ATP-III)  of   National 
Cholesterol Education Program (NCEP) 2 is simpler to use  and has a higher  predictive 
value than the guidelines issued by WHO is used in our study. The NCEP ATP III used 
to diagnose Metabolic Syndrome if three out of five of the following criteria are met.
1. Waist circumference > 102 cm for males, > 88 cm for females
2. Blood pressure ≥ 130/85 mm Hg
3. Fasting blood glucose ≥ 110 mg/dl
4. HDL < 40 mg/dl for males; < 50 mg/dl for females
5. Plasma triglycerides ≥ 150 mg/dl
For defining abdominal obesity these cut of values for waist circumference is not 
universally applicable because of  geographical and ethnic differences. In a attempt to 
overcome such draw backs International diabetes Federation has recently proposed new 
definition based on the regional cut off values for waist circumference which can be 
calculated by the mean plus one standard deviation for normal healthy population of that 
region.  The  waist  circumference  based  on  the  above  statement  for  normal  healthy 
population of Chennai, as per the study of Ramachandran A et al3 is 90cm for males and 
85cm for females.
In  India  current  data  shows,  the  prevalence  of  metabolic  syndrome in  Indian 
population is about 40%4, much higher than 25%5 quoted for western population. The 
southern Indian urban population has highest prevalence rates for metabolic syndrome 
due to genetic predisposition and the tendency to have higher amounts of abdominal fat 
for a given body mass index.
Hypothyroidism  is  a  clinical  syndrome  caused  by  decreased  level  of  thyroid 
hormones. It can be primary in which there is intrinsic disorder of thyroid gland which is 
most common or it may be secondary to pituitary or hypothalamic effects6.
Florid  hypothyroidism  can  be  diagnosed  when  there  is  clinical  symptoms  of 
hypothyroidism and biochemical analysis reveals raised thyroid stimulating hormones 
and  decreased  thyroid  hormones.  TSH  is  the  single  most  parameter  in  screening 
hypothyroidism.   The  normal  TSH  level  rules  out  primary  hypothyroidism but  not 
secondary hypothyroidism.  In presence of raised TSH, a low free thyroid hormone level 
is necessary to confirm hypothyroidism.
Sub clinical hypothyroidism in which patient is asymptomatic and biochemical 
analysis shows only raised TSH level with low normal levels of free thyroid hormones. 
In hypothyroidism initially TSH raises followed by decrease in free T4, and only later in 
severe disease free T3 decreases because, 
• Preferential synthesis of  T3 due to increased TSH action on thyroid gland.
• The efficiency of conversion of  T3 to T4 is increased as free T4 level falls.
Hence free T3 level remains within normal range and is not an useful index of 
thyroid function in hypothyroidism and it should not be requested. Both T4 and T3 are 
bound to plasma proteins like thyroxine binding globulin, transthyretin and albumin.  A 
number of inherited and acquired abnormalities affect thyroid hormone binding proteins 
and causes alterations of total T3 and T4 levels.  Hence our study uses only free thyroxin 
level and thyroid stimulating hormones for assessing thyroid function.
Link between Hypothyroidism and Metabolic syndrome 
LIPID METABOLISM 
Hypothyroidism     ↓BMR
                                       ↓
                          Lipid Accumulation
                                      ↓
                        TGL↑, LDL ↑, HDL ↓
BLOOD PRESSURE 
Hypothyroidism Increases peripheral vascular resistance increasing diastolic BP. 
Hence Hypothyroidism can ↑ TGL, ↑ LDL, ↓ HDL, ↑ abdominal  fat  and also 
cause  hypertension  which  are  components  of  metabolic  syndrome.  Hence  assuming 
patient with ↑ TGL, ↓ HDL, increased abdominal girth and hypertension as metabolic 
syndrome and treating with antilipidemic/ anti hypertensive drugs without measuring 
thyroid function tests won’t be effective if the patient happens to be hypothyroid and 
unless treated with thyroxine. Hence we proceded with our study screen patients with 
metabolic syndrome for thyroid dysfunction.
AIM OF THE STUDY 
To screen patients with DM/ SHT / obesity for features of    
metabolic syndrome as per NCEP ATP III guidelines.
To study prevalence of thyroid dysfunction in patients with 
     metabolic syndrome
To emphasize the need of thyroid function test in patients with 
metabolic syndrome whether necessary or not.
REVIEW OF LITERATURE
Cronological  history of metabolic syndrome
1922
Kylin,  a  Swedish  physician,  described  a  clustering  of 
hypertension, hyperglycemia and gout.
1938
British physician Harold Percival  Hinsworth coins the term 
insulin sensitivity.
1960
Yalow and Berson establish the concept that obesity, whether 
associated with diabetes or not, is a cause of insulin resistance. 
1967
Avogaro and Crepaldi, two Italian researchers, first describes 
a  clustering  of  cardiovascular  risk  factors  (hypertension, 
diabetes, dyslipidemia, and obesity). 
1977
German  research  group  also  describes  a  clustering  of 
cardiovascular risk factors. 
1988
Gerald M. Reaven,MD, from Stanford University School of 
Medicine, first describes syndrome X in a Banting Lecture at 
annual meeting of American Diabetes Association.
2001
Adult  Treatment  Panel  III  of  the  National  Cholesterol 
Education Program proposes diagnostic criteria for metabolic 
syndrome.
2005
International Diabetes Federation (IDF) recognizes that central 
obesity  is  an  important  determinant  of  the  metabolic 
syndrome. 
THE METABOLIC SYNDROME IN A GLOBAL PERSPECTIVE
The concept of the Metabolic syndrome is a well recognized one now all over the 
world and has been proved by a  number  of  studies  to  be an important  predictor  of 
cardiovascular mortality.  The metabolic syndrome is a very common disorder and the 
prevalence rates all over the world has been increasing.
Borch-Johnsen K  reports  in  his  article7 “The metabolic  syndrome in  a  global 
perspective”  that the prevalence of the metabolic syndrome and also of its individual 
components worldwide has been steadily increasing. The article also predicts that by 
2025 AD, it is likely that three out of four persons with the individual syndrome may 
found in one third world countries including South Asia.
INTERHEART  study,  conducted  in  52  countries  has  reported  26%  global 
prevalence of metabolic syndrome8. According to data from third national health and 
nutrition  examination  survey  conducted  between  1988  to  1994,  the  prevalence  of 
metabolic syndrome according to NCEP – ATP III criteria varies from 16% of Afro-
American men to 37% of Hispanic women. This shows there is ethinical, racial, and 
sexual differences affects the prevalence of metabolic syndrome.
Many recent studies have established prevalence of metabolic syndrome is high 
among  Indian  population.  Ramachandran  reported  a  prevalence  rate  of  metabolic 
syndrome is 41% in urban Asian Indian adult population compared to the 26% of global 
population.
The high prevalence  of  the  metabolic  syndrome was not  limited  to  the urban 
population alone, though as expected it was higher in the urban population than the rural 
population.  This higher incidence in urban population may due to the adoption of a 
modernized  life-style  with  high  calorie  diet,  less  physical  activity  and  subsequently 
increased  body  weight.  To  study  the  environmental  and  genetic  influences  on  the 
metabolic syndrome and the effect of modernization over its prevalence, Shobhanjan 
Sarkar, Mithun Das et al9  conducted a study among the tribal population of Bhutias in 
the sub-Himalayan terrain spread over the states of Sikkim, West Bengal and Bhutan. 
The prevalence of the metabolic syndrome was around 50% among the females and 
around 30% among the males using the NCEP – ATP III guidelines.
GENETIC PREDISPOSITION OF THE INDIAN POPULATION TO THE 
METABOLIC SYNDROME
Mohan V et al reported that the South Indian population is all the more prone to 
have a higher prevalence rate for the metabolic syndrome from their Chennai Urban 
Population study (CUSP)10. 
There is now resounding evidence that the Asian Indian population has a racial 
predisposition to the development of the metabolic syndrome.  Epidemiological studies 
have shown that  Asian Indians are more insulin resistant  and this contributes to the 
higher  prevalence  of  the  metabolic  syndrome,  type  II  diabetes  and  cardiovascular 
diseases.   Insulin  resistance  and  hyperinsulinaemia  have  been  demonstrated  as  a 
characteristic  feature  in  Asian  Indians  by  Sharp  and  Mohan13.  Several  studies  have 
shown that there is strong genetic component to insulin resistance.
A main factor contributing to insulin resistance is obesity.  Asian Indians rarely 
have marked obesity  but  they have insulin  resistance even with mild obesity.  Asian 
Indians require more insulin to maintain normoglycemic values.  The features of insulin 
resistance which includes hyperinsulinaemia, upper body adiposity and high body fat 
percentage occurs at a younger age in Asian Indian subjects.  Though body mass index 
(BMI), an indicator of 
obesity is lower among Indians, the waist to hip ratio (WHR) for any given BMI was 
higher among Indians compared to other ethnic groups11.  Furthermore, for any given 
BMI, Indians also have higher body fat and for any given body fat, Indians have higher 
insulin resistance compared to other ethnic groups.  A very recent study on neonates 
compared body weight  and insulin resistance of newborn Indian babies in Pune and 
white babies in London, showed evidence of hyperinsulinaemia and increased body fat 
in Indian babies12,13.
Being  Asian  Indian  confers  a  unique  combination  of  high  risk  factors  for 
cardiovascular disease clustered in a single population.  The Asian Indian phenotype 
also includes the following:
 Hyperinsulinaemia and glucose intolerance are more common in healthy Asian 
Indians.
 Asian Indian obesity phenotype which results in increased visceral adiposity even 
at low BMI.
 High levels of triglycerides, low HDL-C and higher levels of small dense LDL- C 
characterize typical Indian lipid profile.
 Higher  levels  of  procoagulant  plasminogen  activator  inhibitor  –  I  have  been 
demonstrated in Asian Indians.
Higher  levels  of  soluble  cell  adhesion  molecules,  markers  of  endothelial 
dysfunction have been found even in healthy Asian Indians.
 Higher levels of intramyocyte fat deposition have been reported.
 Higher  levels  of  CRP  and  ESR indicating  possibly  intra-plaque  inflammation 
have been reported in Asian Indians.
 Increased urbanization and lifestyle changes have increased levels of obesity and 
hence metabolic syndrome.  This is particularly marked in urban slum dwellers 
and children.
 Adverse environment during fetal life leading to low birth weight as is common in 
our country is associated with greater incidence of insulin resistance later in life.
Being such a high risk group, it is necessary to use different standards for defining 
obesity in our population to be meaningful.  The International Diabetic Foundation has 
come up with values for waist circumferences that are ethnic specific.  Ramachandran 
have brought out cut off values for normal anthropometric variables for Asian Indians.
PROPOSED  COMPONENTS  AND  ASSOCIATED  CHARACTERISTICS  OF 
THE METABOLIC SYNDROME
1. Insulin resistance
2. Hyperinsulinemia
3. Obesity: visceral (central), but also generalized obesity
4. Dyslipidemia: high triglycerides,LDL and low HDL
5. Adipocyte dysfunction
6. Impaired glucose tolerance or type 2 diabetes mellitus
7. Fatty liver (nonalcoholic steatohepatosis, steatohepatitis)
8. Essential hypertension: increased systolic and diastolic blood pressure
9. Endothelial dysfunction 
10. Renal dysfunction: micro- or macroalbuminuria
11.  Polycystic ovary syndrome
12. Inflammation: increased CRP and other inflammatory markers
13. Hypercoagulability: increased fibrinogen and PAI- 1
14. Atherosclerosis leading to increased cardiovascular morbidity and mortality
PATHOPHYSIOLOGY OF METABOLIC SYNDROME
Insulin resistance
Insulin resistance  is  a  common  pathogenic  factor  causing  impaired  glucose 
tolerance/type  II  diabetes,  low  HDL  cholesterol,  increased  triglycerides  and 
hypertension.   Under  normal  physiological  conditions,  plasma  insulin  inhibits  FFA 
release from adipocytes, stimulates muscle glucose disposal and regulates glucose and 
lipid metabolism in liver.  As adipose muscle and hepatic tissues become progressively 
more  insulin  resistant  circulating  FFA  level  increase,  peripheral  glucose  disposal 
declines  and  hepatic  glucose  and  lipoprotein  production  raise  causing  glucose  and 
cholesterol  abnormalities.  Hyperinsulinemia  contributes  to  the  pathogenesis  of 
hypertension by activation of sympathetic nerves system, increased activity of the Na+ / 
H+ exchange pump, increased retention of renal sodium and expansion of circulating 
volume, and increased salt sensitivity.
Insulin resistance is associated with hypertriglyceridemia causes increased VLDL 
particles which stimulates the production of plasminogen activator inhibitor type I (PAI–
I)  by  endothelial  cells  owing  to  enhanced  transcription  of  PAI–I  gene  causing 
hypercoagulable state.
VARIOUS FACTORS CONTRIBUTING TO INSULIN RESISTANCE
        Physical Inactivity                                       Ageing
                      
Obesity                                                            type-2 DM
Heredity               INSULIN RESISTANCE 
 
                                                                        PCOS
     HT                         Dyslipidemia        
                 
Obesity
Although abdomen obesity could lead to insulin resistance and is a prerequisite 
for  metabolic  syndrome  in  the  resent  IDF  definition,  insulin  resistance  can  occur 
irrespective of concomitant obesity and central adiposity.  In the NHANES III study 5 to 
10% of population of BMI 20 to 25 kg/m2 had metabolic Syndrome14. However these 
individual not overtly obese, may have increased deposition of visceral fat. Body fat 
distribution especially  visceral  adipose  tissue  accumulation is  highly  correlated  with 
diabetogenic, atherogenic, prothrombotic and proinflammatory metabolic abnormalities. 
This is mainly due to excessive lipolysis and increased FFA hampering the effect of 
insulin action on muscle tissue.
FFA can also exert a direct toxic effect on the beta – cells causing reduction of 
beta cell mass and impaired insulin secretions.
Inflammatory mediators
The adipose tissue is a major source of inflammatory mediators like TNF – alpha, 
Interlukin  –  6  and  also  haptoglobin.   This  mediators  are  associated  with  enhanced 
hepatic  gluconeogenesis  with  consequent  hyperglycemia  and  compensatory 
hyperinsulinemia.  
Adiponectin
Adiponectin  is  secreted  from  the  adipose  tissue  and  its  levels  are  inversely 
correlated  with  the  adiposity  and  central  fat  distribution,  fasting  plasma  insulin 
concentration and glucose tolerance.
Sympathetic nervous system
The sympathetic drive to heart and peripheral circulation causes increased heart 
rate and increase in both systolic and diastolic blood pressure.  
Genetics
Clustering of metabolic syndrome in families suggests a genetic component.  Not 
all individuals exposed to westernized lifestyle will face an equivalent risk of metabolic 
syndrome.  This  highlights  importance  of  gene  environment  interruptions.  Candidate 
gene analysis shows various genes responsible for development of metabolic syndrome.
ACE (Angiotensin Converting enzyme)  gene insertion / deletion polymorphism 
was associated with metabolic syndrome.  PPAR – γ2  associated with reduced risk. 
Other genes like NOS3 (Nitric Oxide Synthase), PTPN 1 (Protein Tyrosine Phosphatase 
1) gene, IL (interleukin) – 6, BEACON gene, etc., are involved in the pathogenesis of 
metabolic syndrome.
UPREGULATION OF 11-  β  HYDROXY STEROID DEHYDROGENASE 
RECEPTOR
                                            Obesity
                                       Insulin resistance
                                         Inflammation
            Upregulation of 11 –β hydroxyl steroid dehydrogenase - 1
                                    Increase cortisol
   Mineralo corticoid receptor          Gluco corticoid receptor
                                 Hypertension
DIAGNOSING METABOLIC SYNDROME
Several  groups  have  attempted  to  develop  diagnostic  criteria  for  diagnosis  of 
metabolic  syndrome.  The  first  attempt  was  made  by  a  World  Health  Organization 
(WHO) diabetes group in 1999 who proposed that insulin resistance or its surrogates, 
impaired glucose tolerance or  diabetes,  as  essential  components  and at  least  two of: 
raised  blood  pressure,  hypertriglyceridemia  and/or  low HDL  cholesterol,  obesity  as 
measured by body-mass index (BMI) or waist-hip ratio (WHR), and microalbuminuria15. 
The European Group for study of Insulin Resistance (EGIR) in 1999 developed a 
modified version of WHO definition which introduce fasting insulin instead of people 
with diabetes and also introduced waist circumference (94 cm for men and 80 cm for 
women) as a measure of adiposity16.
A  more  pragmatic  approach  was  adopted  by  the  US  National  Cholesterol 
Education  Program:  Adult  Treatment  Panel-3  (ATP-3)  in  2001  with  a  focus  on 
cardiovascular disease risk.  The specific objective was to facilitate a clinical diagnosis. 
It was less glucocentric than earlier definitions and required presence of any three of the 
five components: central obesity, raised BP, raised triglycerides, low HDL cholesterol 
and  fasting  hyperglycemia.  A  major  problem  was  applicability  to  different  ethnic 
groups, especially among East Asians and South Asians.
All of these definitions strongly emphasized abdominal obesity, but cut-off values 
for waist circumference were not universally applicable.  In an attempt to overcome such 
drawbacks,  the International  Diabetes Federation (IDF) has recently proposed a new 
definition  of  MS  including  central  obesity  and  2  metabolic  sequaelae,  in  which 
abdominal  obesity  defined  on  the  basis  of  regional  cut-off  values  for  waist 
circumference becomes central to the diagnosis17.  The corrected values for the waist 
circumference for Indian Asians is 90 cm for men and 80 cm for the women.  The same 
values of waist circumference are also used for the Modified NCEP- ATP III guidelines.
COMPARISON  OF  ADULT  TREATMENT  PANEL  (ATP)  III  AND  WORLD 
HEALTH  ORGANIZATION  (WHO)  CRITERIA  FOR  THE  DIAGNOSIS  OF 
THE METABOLIC SYNDROME.
Risk Factor ATP III Defining level WHO Defining Level
1. Obesity Waist circumference 
>102 cm (>40 in) for 
men and >88 cm (>35 in) 
for women
Body mass index (BMI) 
≥30 kg/m2 and/or waist- 
to-hip ratio of >0.90 for 
men and >0.85 for 
women 
2. Blood Pressure ≥130/≥85 mmHg >140/ >90 mmHg
3. Fasting Glucose ≥110 mg/dL Type II 
diabetes,impaired GTT 
or insulin resistence by 
HOMA-IR
4. Microalbuminuria Not used for diagnosis Urinary albumin 
excretion rate ≥20 
µg/min
5. Triglycerides ≥150 mg/dL ≥150 mg/dl
6. HDL Cholesterol <40 mg/dL for men
<50 mg/dL for women
<35 mg/dL for men
<39 mg/dL for women
The NCEP- ATP III definition is simpler and can easily be applied to the general 
population. Hunt reported that the NCEP definition of the Metabolic Syndrome was of 
more  predictive  value  than  the  WHO definition  even in  low-risk  subjects.  Also  the 
NCEP definition was better predictive of all cause and cardiovascular mortality in both 
men and women than the WHO definition in the San Antonio Heart Study.
The  NCEP-  ATP  III  guidelines  were  used  for  the  diagnosis  of  metabolic 
syndrome with necessary modification for the waist circumference  ≥ 90 cm for the men 
and ≥ 80 cm for the women in our study.
INTERNATIONAL DIABETIC FEDERATION DEFINITION ON METABOLIC 
SYNDROME (2005)
Central  obesity  according  to  the 
waist Circumference plus any two 
of the following four criteria.
Ethni specific:
South Asians  ≥ 90 cm for men; 
≥80 cm for women.
Raised triglycerides ≥150 mg/dl
Low HDL <40 mg/dl for men
<50 mg/dl for women
High Blood Pressure ≥130/85 mm Hg
Fasting Blood Glucose ≥110 mg/dl
HYPOTHYROIDISM
PHYSIOLOGY OF THYROID HORMONES
Thyroxin T4 and triiodothyronine T3 are the principle hormones produced by the 
thyroid gland.  Ingested iodine is absorbed from the gut gets converted to iodide and 
bounds to serum albumin and transported through the blood.  Thyroid gland actively 
extracts iodide from the circulation by iodide trapping mediated by Na+ / I- sympoter 
(NIS).  The NIS mediated iodide transport is highly regulated, i.e,  low iodide levels 
increases NIS and increases iodide uptake and vice versa. The trapped iodide is oxidized 
to  iodine  and  this  reactive  iodine  atom  is  added  to  selected  thyrosyl  residues  in 
thyroglobulin  (Tg)  by  the  process  called  organification forming  iodothyrosin.  This 
iodothyrosin  forms  T4  or  T3  by  coupling.  Oxidation,  organification  and  coupling 
reactions  are  catalised  by  thyroid  peroxidase.  Thyroid  hormones  thus  produced  are 
bound to thyroglobulin and secreted.
Once  secreted  in  blood  it  is  bound  to  thyroid  binding  globulin  (TBG), 
Transthyritin and albumin and remaining as free hormones which is active.
CONTROL OF THYROID HORMONES
Thyroid stimulating hormone (TSH)  controls the secretion of T3 and T4. It is 
secreted  in  a  pulsatile  manner  with  peak  secretion  in  the  night.  TSH  secretion  is 
stimulated by thyroid releasing hormone (TRH).  Both TRH and TSH release are under 
negative feedback of free T3     and T4.
 Hypothalamus     _ 
         +
Pitutary                 _  
         +
Thyroid gland
T4--------------- T3
Peripheral action
ACTIONS OF THYROID HORMONES
Thyroid hormones acts by binding to the nuclear thyroid hormone receptors TRs α 
and TRs β. TRs α is abandon in brain, kidney, gonad, muscle and heart.  TRs β is high in 
pituitary, hypothalamus and liver and is responsible for feedback control of thyroid axis. 
FT3 has 10 to 15 times greater affinity than FT4 to TRs α and TRs β which explains the 
increased potency of free T3.  The receptor sites are mainly occupied by T3. 
SIGNS AND SYMPTOMS OF HYPOTHYROIDISM
The following are symptoms of hypothyroidism: 
• Fatigue, loss of energy, lethargy 
• Weight gain 
• Decreased appetite 
• Cold intolerance 
• Dry skin 
• Hair loss 
• Sleepiness
• Muscle pain, joint pain, weakness in the extremities 
• Depression 
• Emotional lability, mental impairment 
• Forgetfulness, impaired memory, inability to concentrate 
• Constipation 
• Menstrual disturbances, impaired fertility 
• Decreased perspiration 
• Paresthesia and nerve entrapment syndromes 
• Blurred vision 
• Decreased hearing 
• Fullness in the throat, hoarseness
The following are symptoms more specific to Hashimoto thyroiditis:
• Feeling of fullness in the throat 
• Painless thyroid enlargement 
• Exhaustion 
• Neck pain, sore throat, or both 
• Low-grade fever
Signs found in hypothyroidism are usually subtle and require a careful physical 
examination.  Often,  many signs are dismissed as part  of aging;  however, consider  a 
diagnosis of hypothyroidism when such signs are present.
Physical signs of hypothyroidism include the following:
• Hypothermia 
• Weight gain 
• Slowed speech and movements 
• Dry skin 
• Jaundice 
• Pallor 
• Coarse, brittle, strawlike hair 
• Loss of scalp hair, axillary hair, pubic hair, or a 
combination 
• Dull facial expression 
• Coarse facial features 
• Periorbital puffiness 
• Macroglossia 
• Goiter 
• Hoarseness 
• Decreased systolic blood pressure and increased diastolic 
blood pressure 
• Bradycardia 
• Pericardial effusion 
• Abdominal distension, ascites is uncommon. 
• Nonpitting edema (myxedema) 
• Pitting edema of lower extremities 
• Hyporeflexia with delayed relaxation, ataxia, or both
LINKING METABOLIC SYNDROME WITH HYPOTHYROIDISM
Subclinical  hypothyroidism  (SCH)  is  a  prevalent  condition  among  adult 
population,  however  it  is  frequently  overlooked.  Thyroid  functions  affect  metabolic 
syndrome  parameters  including  HDL  cholesterol,  triglycerides,  blood  pressure  and 
plasma  glucose.  On  the  other  hand,  the  relation  between  Metabolic  Syndrome  and 
thyroid dysfunction is not clearly identified yet. The aim of the  study conducted by 
Goztepe  training  and  research  hospital18 was  to  investigate  the  prevalence  of  SCH 
among  Metabolic  Syndrome  patients  and  to  identify  its  relation  with  Metabolic 
Syndrome  parameters.  Two  hundred  and  twenty  Metabolic  Syndrome  patients 
(Metabolic  Syndrome group; 167 female,  53 male,  mean age:  48.5  + 11.3)  and 190 
patients without Metabolic Syndrome (Control group; 142 female, 48 male, mean age: 
46.3  + 11.9)  attending  consecutively  to  Internal  Medicine  outpatient  clinics  were 
included in this study. Groups were compared in terms of SCH prevalence. SCH was 
defined as a condition with high thyrotrophin and normal free thyroxine levels. SCH was 
found in 36 (16.4%) cases in the Metabolic Syndrome group and in 11(5.8%) cases in 
the control group (p = 0.001). Only female gender was associated with the presence of 
SCH. About one sixth of Metabolic Syndrome patients had SCH. This finding indicates 
a  need for  investigating  the  presence  of  SCH during  the  management  of  Metabolic 
Syndrome patients. 
Study  conducted  by  Departments  of  Endocrinology  and  Internal  Medicine, 
University  Medical  Center  Groningen  and  University  of  Groningen,   Netherlands19 
included  2703 adult inhabitants of a middle-sized city in the Netherlands,  in this cross-
sectional study. Subjects on thyroid hormone replacement therapy or thyroid blocking 
agents and subjects taking medication for dyslipidemia and/or diabetes were excluded. 
Since most patients with the metabolic syndrome will have normal thyroid function, we 
also  excluded  aneuthyroid  subjects.  The  HOMA  index  for  insulin  resistance  was 
calculated on the basis of fasting glucose and insulin levels.
 Results  showed Significant,  but  weak positive  correlations  (all  P<0.05)  were 
found  between  TSH  and  HDL-C  (r=0.06)  and  triglycerides  (r=0.06).  Significant 
negative correlations were found between: FT4 and total cholesterol (r=−0.06), LDL-C 
(r=−0.05), TG (r=−0.08) and Apo B (r=−0.05); FT3 and total cholesterol (r=−0.08), 
HDL-C (r=−0.05),LDL-C (r=−0.06)  and  Apo  B  (r=−0.06).  FT4  (but  not  FT3)  was 
negatively correlated with HOMA index (r=−0.14). The metabolic syndrome (according 
to NCEP ATP III  criteria)  was present  in 21.0% of women and 16.6% of men and 
increased with age.  FT4 in subjects with a metabolic syndrome was significantly lower 
than in subjects without a metabolic syndrome (12.6±1.7 vs 12.9±1.8 pmol/l; P=0.04)
The study concluded an association between thyroid function and lipid levels in 
subjects  classified  as  being  euthyroid,  in  accordance  with  the  earlier  observed 
association between (sub) clinical hypothyroidism and hypercholesterolemia. Moreover, 
low normal FT4 levels were significantly associated with increased insulin resistance. 
This implicates that subjects with low-normal thyroid function already have increased 
cardiovascular risk.            
   Another  study   conducted  by  Department  of  Biochemistry,  B.  P.  Koirala 
Institute of Health Sciences, Dharan, Nepal20 for  association of metabolic syndrome and 
its  components with thyroid dysfunction in females.   It  was a hospital  based,  cross-
sectional study which included One hundred females subjected to thyroid function tests 
(FT 3, FT 4 and TSH) with their consent.  Results showed The prevalence of metabolic 
syndrome was 32%, more in euthyroid group (21/48) than hyperthyroid group (5/24) 
and hypothyroid group (6/28). Hence the study concluded that the thyroid dysfunction 
may be protective for the development of metabolic syndrome. Cross-sectional study 
which included one hundred females subjected to thyroid function tests (FT3, FT4 and 
TSH) with their consent.  Results showed
 
the prevalence of metabolic syndrome was 32%, more in euthyroid group (21/48) than 
hyperthyroid group (5/24) and hypothyroid group (6/28). Hence the study concluded that 
the thyroid dysfunction may be protective for the development of metabolic syndrome.
LINKING DIABETES MELLITUS WHICH IS A COMPONENT OF 
METABOLIC SYNDROME WITH HYPOTHYROIDISM
Minerva endocrinologia 200522, study shows the prevalence of thyroid disease in 
diabetes patient is 2 to 3 times higher than in non diabetic subjects. They also concluded 
increased  frequency  of  hypoglycemia  in  hypothyroidism  and  development  of 
ketoacidosis  in  hyperthyroidism and  recommended  screening  by  thyroid  functioning 
tests.
Evaluation of thyroid function out of 161 diabetic patients in calabar, Nigeria23 
showed  46.5%  have  abnormal  thyroid  hormone  levels.  Among  these  26.6%  have 
hypothyroidism and 19.9% have hyperthyroidism.  The prevalence of hypothyroidism 
was higher in women 16.8% than in men 9.9%, while hyperthyroidism was higher in 
men 11% than in women 8%.
Survey of hypothyroidism in diabetic patient in American – Indian population by 
journal of family practice, July 200021 stated the overall prevalence of hypothyroid in 
diabetic patients is 8.8% varied by age ranging from 5% among women younger than 60 
years to 21%  among women aged 60 and above.
These studies clearly shows abnormal thyroid function can occur in patients with 
metabolic syndrome and also in diabetes patients which is a component of metabolic 
syndrome.
HIGHLIGHTING PARAMETERS WHICH IS COMMON TO BOTH 
METABOLIC SYNDROME AND HYPOTHYROIDISM
Metabolic syndrome Hypothyroidism
Blood Pressure Increase in systolic and 
diastolic BP
Increase in diastolic 
BP
Triglyceride Increase Increase
HDL cholesterol Decrease Decrease
Diabetes mellitus/ 
impaired GTT 
One of the component of 
metabolic syndrome
May be associated
Insulin resistance Major component of 
pathogenesis
Can occur
Obesity Important and most 
essential component 
according to FDA 
Often associated
Since the literature shows various association between metabolic syndrome and 
thyroid  function,  and  sharing  of  components  of  metabolic  syndrome  and 
hypothyroidism,  we proceeded in  studying analysis  of  thyroid function in  metabolic 
syndrome patients. 
SUBCLINICAL HYPOTHYROIDISM
"Subclinical  hypothyroidism,"  is  most  commonly  an  early  stage  of 
hypothyroidism  associated  with   increased  thyrotropin-stimulating  hormone  (TSH) 
levels in patients whose free thyroxine (T4) levels are not below normal.  Although the 
condition may resolve or remain unchanged, within a few years in some patients, overt 
hypothyroidism develops, with low free T4 levels as well as a raised TSH level. The 
likelihood that this will happen increases with greater TSH elevations and detectable 
antithyroid  antibodies.  Because  patients  with  subclinical  hypothyroidism  sometimes 
have  subtle  hypothyroid  symptoms  and  may  have  mild  abnormalities  of  serum 
lipoproteins and cardiac function, patients with definite and persistent TSH elevation 
should be considered for thyroid treatment. Levothyroxine, in a dosage that maintains 
serum TSH levels within the normal range, is the preferred therapy in these patients.
Screening for subclinical hypothyroidism
Hypothyroidism older persons is quite common in. In one study,24 thyrotropin-
stimulating hormone (TSH) levels greater than 10 µU per Ml     (10 mU per L) were 
found in 7 percent of women and 3 percent of men who were 60 to 89 years of age, 
living active lives in the community (normal range: approximately 0.5 to 4.5 µU per mL 
(0.5 to 4.5 mU per L). Clinical suspicion of hypothyroidism may be delayed in elderly 
patients  because  symptoms  such  as  fatigue  and  constipation,  and  other  early 
manifestations of thyroid failure may be attributed to aging itself. The high prevalence 
of thyroid failure and the difficulty of making an early clinical diagnosis in older persons 
suggest that screening for hypothyroidism might be useful in this group, especially since 
a  simple  test,  the  serum  TSH  level,  is  available.  Recommendations  about  thyroid 
screening,  however,  have  been  inconsistent.  Currently,  no  organizations  recommend 
routine universal screening. For example, the U.S. Preventive Services Task Force25 has 
recommended that asymptomatic adults not be screened because evidence of clinical 
benefit  is  insufficient.  More  recently,  some  authors26 have  recommended  testing  in 
women more than 40 years of age and in patients in geriatric facilities. Danese and co-
workers27 demonstrated through a decision model that TSH screening every five years, 
starting at age 35, was cost-effective because progression to overt hypothyroidism was 
prevented,  serum cholesterol  levels  were  reduced  and symptoms were  relieved with 
early treatment of hypothyroidism.
Measurement of serum TSH is generally considered the best screening test for 
thyroid disease; increased values usually indicate hypothyroidism, and decreased values 
usually indicate hyperthyroidism. This test has proved to be both sensitive and specific. 
Its very sensitivity, however, may create a dilemma, since some patients are found to 
have elevated serum TSH levels, suggesting hypothyroidism, but have normal levels of 
thyroid hormone, whether measured as free thyroxine (T4) or free T4 index.
This state an elevated TSH level  with a normal free T4 level is  referred to as 
subclinical  hypothyroidism.  The term "subclinical" may not  be strictly correct,  since 
some  of  these  patients  may  have  clinical  symptoms,  but  no  better  term  has  been 
proposed.  The  elevation  of  TSH levels  reflects  the  sensitivity  of  the  hypothalamic-
pituitary axis to small decreases in circulating thyroid hormone; as the thyroid gland 
fails, the TSH level may rise above the upper limit of normal whenthe free T4 level has 
fallen  only  slightly  and  is  still  within  the  normal  range.  Clinical  manifestations,  if 
present, may be explained by assuming that a totalT4 level of 6 or 7 µg per dL (77 to 90 
nmol per L), although not outside the normal range of 4.5 to 12.5 µg per dL (58 to 
160 nmol per L), may represent a significant fall from an original level of 9 or 10 µg per 
dL (116 to 129 nmol per L) and, thus, is low for this particular patient.
Causes
Subclinical hypothyroidism is caused by the same disorders of the thyroid gland 
as those that  cause overt hypothyroidism. Chief among these is  chronic autoimmune 
thyroiditis (Hashimoto's disease), which is commonly associated with increased titers of 
antithyroid  antibodies,  such  as  antithyroid  microsomal  antibodies  (antithyroid 
peroxidase) and antithyroglobulin antibodies.28 This disorder is suspected when thyroid 
enlargement is observed, but antithyroid antibodies may also be associated with atrophy 
of the thyroid and hypothyroidism.
Course
In some cases, the TSH level will be normal if measured again several months 
later; we would then attribute the initial elevation to laboratory error or, perhaps, to an 
episode  of  silent  thyroiditis  with  a  transient  hypothyroid  phase.  In  other  cases,  the 
subclinical  hypothyroidism remains  unchanged.  The  third  possibility,  progression  to 
overt hypothyroidism, occurs at a rate of about 5 percent per year in patients with raised 
TSH  levels  and  detectable  antithyroid  antibodies.31 In  selected  cases  (e.g.,  elderly 
patients  with  high  titers  of  antithyroid  antibodies),  the  risk  of  progression  to  overt 
disease may be closer to 20 percent per year.32 Consideration of these possible outcomes 
affects the decision about whether to treat or to observe without treatment.
Manifestations
The clinical signs and symptoms of hypothyroidism manifest when the disease is 
fully  developed.  But  even  in  the  earliest  (subclinical  stage),  one  or  more  of  these 
findings  may  occur.  In  one  study,33 symptoms  in  33  patients  with  subclinical 
hypothyroidism were compared with symptoms in 20 euthyroid patients in the same 
thyroid clinic. Dry skin, cold intolerance and easy fatigability were significantly more 
common in the patients with raised TSH levels,  and these symptoms improved after 
treatment with thyroid hormone. In another study34 of 69 female patients with subclinical 
hypothyroidism, a clinical index based on symptoms and physical signs was shown to be 
more abnormal in patients with higher TSH levels, even though all patients had normal 
serum levels of T4 and free T4. These studies suggest that some patients with subclinical 
hypothyroidism do indeed have clinical manifestations of mild thyroid failure.
Serum Lipids 
In  patients  with  full-blown hypothyroidism serum levels  of  triglycerides,  total 
cholesterol and low-density lipoprotein (LDL) cholesterol are elevated. In patients with 
subclinical hypothyroidism, not surprisingly, the same changes are present but are less 
marked and less consistent. This pattern of lipid abnormalities, of course, is important 
because it is a risk factor for atherosclerotic cardiovascular disease. Some studies,35,36but 
not others,10 have shown a decrease in LDL cholesterol and total cholesterol levels after 
treatment with levothyroxine 
Cardiac Function 
In several studies, a sensitive measure of myocardial contractility, the ratio of pre-
ejection  period to  left  ventricular  ejection time (PEP:LVET) was shown to improve 
significantly  in  patients  with  subclinical  hypothyroidism  who  were  treated  with 
levothyroxine, compared with patients who were treated with placebo.33,37
Should We Treat Subclinical Hypothyroidism?
Indications for treatment in subclinical hypothyroidism are not established, but 
general guidelines can be offered. Greater magnitude and duration of TSH elevation and 
higher titers of antithyroid antibodies increase the probability that the condition will 
progress  to  overt  hypothyroidism  and,  therefore,  increase  the  potential  benefit  of 
treatment with levothyroxine. The presence of symptoms that might be related to mild 
hypothyroidism also increases the potential benefit of treatment. Risk of harm to the 
patient, against which this potential benefit must be balanced, is quite small, since the 
use of the sensitive TSH assay provides assurance that we are not raising the blood 
thyroid hormone levels too much as long as TSH levels do not fall below the normal 
range. In patients with coronary artery disease and minimal elevations of TSH, however, 
it may be advisable to follow the TSH level rather than subject the patient to the small 
risk of levothyroxine therapy.
In  short,  it  seems  reasonable  to  treat  patients  who  have  a  TSH level  that  is 
consistently  elevated  above  10  µU  per  mL  (10  mU  per  L),  especially  if  titers  of 
antithyroid antibodies are increased. Also, patients who complain of fatigue, dry skin, 
constipation,  muscle  cramps  or  other  common  symptoms  of  hypothyroidism  may 
possibly benefit from treatment even if their TSH level is elevated only into the 5 to 10 
µU per mL (5 to 10 mU per L) range
ALGORITHM  FOR  THE  MANAGEMENT  OF  SUBCLINICAL 
HYPOTHYROIDISM.
           (T4= thyroxine; TSH= thyrotropin-stimulating hormone)
Treatment
Treatment is similar to that recommended in patients with   overt hypothyroidism. 
Levothyroxine  is  the  agent  of  choice,  rather  than  a  preparation  containing  tri-
iodothyronine T3,  since  T3 has a  short  half-life  and requires  multiple  daily  doses  to 
maintain blood levels in the normal range. Levothyroxine, however, has a long half-life 
(approximately seven days) and is partially converted to T3 in the body, resulting in a 
constant physiologic blood level of both T4 and T3 with a single daily dose. In patients 
with overt hypothyroidism, the average daily replacement dosage of levothyroxine is 75 
to 125 µg, or 50 to 100 µg in the elderly, or about 1.6 µg per kg per day. Treatment is 
commonly initiated with 25 to 50 µg daily and raised by increments of 25 to 50 µg, 
according to TSH measurements  at  six-  to eight-week intervals.  In patients who are 
elderly  or  debilitated,  or  who have  heart  disease,  lower  starting dosages and slower 
increases are advisable.
Patients with subclinical hypothyroidism, because of the minimal extent of the 
thyroid hormone deficiency, may be controlled with total daily dosages of levothyroxine 
as low as 25 to 50 µg. This initial dosage should be maintained for six to eight weeks 
before a TSH measurement is repeated to guide adjustment of the levothyroxine dosage. 
The goal is to maintain the TSH level within normal limits; the dosage of levothyroxine 
should be increased if the TSH level remains above normal and should be decreased if 
the TSH level falls below normal. Once the correct dosage of thyroxine is established, 
the  frequency of  TSH measurement  may be decreased to  every  six  to  12 months.A 
common error is the failure to decrease the levothyroxine dosage if the TSH level is 
suppressed below the normal range, which may occur without the free T4 level rising 
above normal. This state is considered to represent "subclinical hyperthyroidism," and 
although formerly it was thought to be harmless, it is now believed to be associated with 
undesired  effects  on  bone  density  (osteoporosis)  and  cardiac  function,  and  to  be  a 
possible  cause  of  neuropsychologic  symptoms  and  other  mild  manifestations  of 
hyperthyroidism.39,40 
Reported prevalence of SCH in literature varies. According to the 1996 Report of 
the U.S. Preventive Services Task Force, SH is found in     6-8% of adult females and 
3% of adult males, with approximately 20-24% of elderly SCH patients testing positive 
for thyroid antibodies eventually developing overt hypothyroidism within several years. 
SCH becomes  more  prevalent  with  age  32,33,34.  SCH is  common among middle-aged 
women most often after menopause, as indicated by an associated increased prevalence 
of serum antibodies thought to be directed toward a microsomal antigen labeled thyroid 
peroxidase30. For purposes of this article, the diagnosis of SCH is defined as a TSH level 
of >4.0 mU/L with a normal free T4 level unless otherwise specified30,31,35.
According to the Whickham Survey 34 in which a random sample of 2779 adults 
were  observed  for  thyroid  disease  over  a  20-year  period,  an  increased  risk  for 
hypothyroidism among  women  was  found.  In  this  long-term study,  the  annual  risk 
among women of developing hypothyroidism was 4.3% per year if both an elevated 
serum TSH and anti-thyroid antibodies were found, 2.6% with elevated TSH alone, and 
2.1% per year with positive anti-thyroid antibodies alone. The study also demonstrated 
that, independent of age, the higher the serum TSH level is above 2 mU/L, the greater is 
the  likelihood  of  developing  overt  hypothyroidism  with  or  without  anti-thyroid 
antibodies. 
Sadovsky, in his review article, noted that patients with SCH based on serum TSH 
levels of >5.0 with a normal free T4 level,  are at  risk for hypercholesterolemia and 
eventual  overt  hypothyroidism.  Further  stated  is  the  uncertainty  of  treatment 
effectiveness, however clinical follow-up of patients with TSH levels between 5.0-10.0 
mU/L  is  recommended.  Clinicians  are  encouraged  to  consider  thyroid  replacement 
therapy in patients with a serum TSH of >10.0 or with positive antithyroid antibodies .
MATERIALS AND METHODS
With the aim of studying the prevalence subclinical hypothyroidism and clinical 
hypothyroidism in patients with metabolic syndrome as per NCEP ATP-III guidelines in 
Govt. Stanley Medical College hospital over a period of ten months from January 2008 
to October 2008 this study was conducted.
METHODOLOGY
The selection of patients for the study was made as follows:
• Patients attending hypertension, diabetology and  general OPD where screened for 
components of metabolic syndrome 
• Those patients who fit into the criteria of MS where screened for thyroid function 
test. 
• Other  parameters  of  target  organ damage which appears  as  a  complication  of 
metabolic syndrome where screened for creatinine, ECG,ECHO for those with 
ECG  changes, liver functions tests and abdomen ultrasound for those with liver 
symptoms and CT-scan brain for those with TIA symptoms.
PATIENT SELECTION 
 Measurement of BP
Patients are screened for the components as follows;
• Same mercury manometer BP apparatus was used for all patients.
 
• Recording was done in the morning hours.
• The BP was measured with the patient relaxed, after a period of resting for five 
minutes,  in  the  sitting  position,  with  the  back supported  and the  arm slightly 
flexed and supported and at the level of heart.
• The cuff with proper width was used to measure the BP. The normal adult cuff of 
with 12.5 cm and length 25 cm was used.
• It was ensured that the cuff covered atleast 80% of the arm circumference and 
covered 2/3rd the length of the arm.  
WAIST CIRCUMFERENCE
• The waist circumference was measured at the mid point between the lower most 
point of ribcage and a point 2 cm above the iliac crest.
• It  was  measured  using  a  flexible  meter  tape  with  the  abdomen  relaxed  after 
loosening all garments and baring the waist region.
• It was measured in the standing position and average of two readings taken as the 
waist circumference.
FASTING BLOOD GLUCOSE
The blood sample for fasting blood glucose was taken after an overnight fast of 
atleast 8 hours and send to biochemistry lab.  
LIPID PROFILE
The blood sample for lipid profile was taken after an overnight fast of twelve hour 
fast and sent to lab for test to be done using autoanalyser using standard procedures.
ESTIMATION OF THYROID FUNCTION TEST
Thyroid stimulating hormone(TSH)
• TSH is the single most parameter to screen hypothyroidism but a normal TSH 
rules out primary hypothyroidism but not secondary hypothyidism. 
• Normal value-0.4 to 4.0mu/l
Free Thyroxine(FT4)
• Only free hormone estimation is  used in our test because total 
hormones are bound to proteins and their levels vary according to the protein 
levels
• Only freeT4 is used in our study because free T3 levels are not affect or only 
affected later in severe hypothyroidism as stated earlier.
• Normal value-0.8 to 1.9pg/ml
EXCLUSION CRITERIA
• Patients  taking  drugs  which  alter  thyroid  profile  like  iodine  containing  drugs 
amiodarone, steroids, phenytoin, estrogen pills and beta-blockers. 
• Patients with acute severe illness which can cause abnormalities of circulating 
TSH and thyroid hormones in the absence of underlying thyroid disease.
• Patients with renal failure/significant proteinuria.
OBSERVATIONS
Fifty metabolic syndrome patients attending hypertension clinic, diabetology OP 
and medicine OP were randomly screened.  The same population consist of 25 males 
and 25 females.
These patients were divided into three sub-groups based on the TSH values. TSH 
< 4 mU/l as euthyroid group, TSH 4- 20 mU/l as subclinical ypothyroid and TSH >20 
mU/l as clinical hypothyroidism. From these groups  the following data were  obtained.
FREQUENCIES OF  METABOLIC SYNDROME PATIENTS AMONG 
THE TSH SUBGROUPS
            
TSH
Male Female Male + Female
No.of 
Patients %
No.of 
Patients %
No.of 
Patients %
<4 18 72 15 60 33 66
4–20 6 24 8 32 14 28
>20 1 4 2 8 3 6
This  shows  33  patients  were  euthyroid,  14  patients  have  subclinical 
hypothyroidism and 3 patients have clinical hypothyroidism which were 66%, 28% and 
6%  respectively.  There  is  slightly  higher  incidence  of  female  patients  developing 
metabolic syndrome than males.


COMPARING THE COMPONENTS OF MET.SYN AND FREE T4 AMONG 
THE TSH SUBGROUPS
FREE T4
No.of 
Patients MEAN SD SE
below 4 33 1.39 0.48 0.08
4 to 20 14 1.02 0.33 0.09
above 20 3 0.3 0.04 0.02
WAIST CIRCUMFERENCE
No.of 
Patients MEAN SD SE
below 4 33 92.30 6.79 1.18
4 to 20 14 92.71 8.52 2.28
above 20 3 96.67 2.08 1.20
TRIGLYCERIDES
No.of 
Patients MEAN SD SE
below 4 33 179.03 65.86 11.46
4 to 20 14 172.79 67.15 17.95
above 20 3 195.33 101.26 58.46
HDL
No.of 
Patients MEAN SD SE
below 4 33 39.42 4.94 0.86
4 to 20 14 38.93 7.07 1.89
above 20 3 33.33 5.13 2.96
F            
          
          
DISCUSSION
Estimate of hypothyroidism prevalence in Leida, Spain shows The prevalence of 
hypothyroidism is 8.4 cases per 1000 Inhabitants; 2.4 cases per 1000 among males and 
12.4 cases 1000 among females. By age groups: Under age 15; 6 cases per 1000, 15-64 
age  groups  6.8 cases per1000 and those  over  age  64,  12.5 cases 1000.  The highest 
figures were found in the rural areas  10.5 cases per 1000 and the lowest in urban areas 
5.8 cases per 1000. This study concluded that Hypothyroidism under treatment figure is, 
as in other studies, higher among females and predominant among those over 64 years 
of age41.
The Third National Health and Nutrition Examination Survey (NHANES III) of 
17,353 individuals reflecting the US population reported hypothyroidism (defined as 
elevated TSH levels) in 4.6% of the population (0.3% overt and 4.3% subclinical)42.
Sub-clinical hypothyroidism was found in 9.5% of self selected US population 
according to Colorado thyroid disease prevalence study43.
Clinically apparent acquired impairment of thyroid function affects about 2% of 
adult women and about 0.1 to 2% of adult men according to Whickham survey44. 
The prevalence of sub clinical  hypothyroidism as per Harrison’s,  Principles of 
Internal Medicine is 6 to 8% in women (10% over the age of 60) and 3% in men.  The 
annual  risk  of  developing  clinical  hypothyroidism  is  about  4%  when  sub  clinical 
hypothyroidism is associated with positive TPO antibodies.   
The prevalence of sub clinical hypothyroidism and clinical hypothyroidism in our 
study where  28% and 6% respectively  in  metabolic  syndrome patients  which is  far 
higher than in general population .This may be due the following reasons; 
 Small size of study population
 Previous study estimates the prevalence of hypothyroidism in general 
population but our study in those with metabolic syndrome
 Metabolic syndrome and hypothyroidism share some common pathway of 
pathogenesis of its clinical features like insulin resistance.
 A truly hypothyroid patient may be labled as metabolic syndrome patients 
because of its common clinical features like hypertension, abnormal lipid 
profile , obesity etc.
The proportion of subclinical and clinical hypothyroidism in metabolic syndrome 
patients in our study is slightly more common in female study group than males 
Comparing  the  average  HDL  values  between  euthyroid,  subclinical 
hypothyroidism and clinical hypothyroidism shows a slightly decreased value of HDL in 
subclinical  hypothyroidism  than   and  a  moderately  decreased  HDL  in  clinical 
hypothyroidism 
Comparing  the  average  triglyceride  values  shows  a  slightly  lower  value  of 
triglyceride in  subclinical  hypothyroid than euthyroid patients  and a  higher  value in 
clinical hypothyroidism. 
Those patients with subclinical hypothyroidism had low normal values of free T4 
than patients with normal thyroid function. This low free T4 level is associated with 
increased insulin resistance as already stated19  
PREVALENCE OF SUB-CLINICAL HYPOTHYROIDISM IN GENERAL 
POPULATION VS PATIENTS WITH METABOLIC SYNDROME
PREVALENCE OF CLINICAL HYPOTHYROIDISM IN GENERAL 
POPULATION VS PATIENTS WITH METABOLIC SYNDROME
Comparing  the  prevalence  of  Sub  clinical  hypothyroidism  among  metabolic 
syndrome by Goztepe training and research hospital with our study.
In  Goztepe  training  and  research  hospital,  the  prevalence  of  SCH  in  met. 
Syndrome patients was higher than  the control groups,  but only female gender was 
associated with SCH. Our study shows much higher prevalence of SCH than previous 
study and both male and female had SCH even though there is less incidence among 
males.
SUMMARY AND CONCLUS  ION  
50  patients  (25  males  and  25  females)  with  metabolic  syndrome  attending 
medicine, diabetes and hypertension OPD in Stanley medical college where analysed for 
thyroid dysfunction.
• The prevalence of subclinical hypothyroidism and clinical hypothyroidism were 
28% and 6% respectively which is far higher than in general population.
• There  is  slightly  higher  prevalence  of  female  patient  developing  thyroid 
dysfunction than males.
• Those  patients  with  subclinical  hypothyroidism  (raised  TSH)  had  subnormal 
levels of freeT4.
• Thyroid dysfunction causes variations in the lipid profile
Since our study shows significant proportion of patient with metabolic syndrome 
had thyroid  dysfunction  and clinical  manifestation  like  hypertension  ,abnormal  lipid 
profile and obesity coexist in both ,it is mandatory to screen thyroid function for patients 
with metabolic syndrome. 
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PROFORMA
Name:                                Address & Ph. No:
Age:            Sex:                Occupation:
OP. No:        IP. No:
HISTORY:
Diabetes:             Hypertension:                 Weight Gain:
↓Appetite:           Constipation:                   Cold Intolerance:
TREATMENT HISTORY:
Height:        Weight:        BMI:
Waist:          HIP:                Waist / HIP Ratio:
Thyromegaly:                Acanthosis Nigaricans:
Blood Pressure:
Fasting Blood Glucose:                      Creatinine:
Cholesterol:         Triglycerides:        HDL:           LDL:            VLDL:
TSH:                    T4:                         Free T4:
Urine Albumin:       Sugar:                Deposits:
ECG:
USG Abdomen:
